<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35658801</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8409</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Expert review of clinical immunology</Title><ISOAbbreviation>Expert Rev Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>Is post-COVID syndrome an autoimmune disease?</ArticleTitle><Pagination><StartPage>653</StartPage><EndPage>666</EndPage><MedlinePgn>653-666</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/1744666X.2022.2085561</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Post-COVID syndrome (PCS) is recognized as a new entity in the context of SARS-CoV-2 infection. Though its pathogenesis is not completely understood, persistent inflammation from acute illness and the development of autoimmunity play a critical role in its development.</AbstractText><AbstractText Label="AREAS COVERED">The mechanisms involved in the emergence of PCS, their similarities with post-viral and post-care syndromes, its inclusion in the spectrum of autoimmunity and possible targets for its treatment.</AbstractText><AbstractText Label="EXPERT OPINION">An autoimmune phenomenon plays a major role in most causative theories explaining PCS. There is a need for both PCS definition and classification criteria (including severity scores). Longitudinal and controlled studies are necessary to better understand this new entity, and to find what additional factors participate into its development. With the high prevalence of COVID-19 cases worldwide, together with the current evidence on latent autoimmunity in PCS, we may observe an increase of autoimmune diseases (ADs) in the coming years. Vaccination's effect on the development of PCS and ADs will also receive attention in the future. Health and social care services need to develop a new framework to deal with PCS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anaya</LastName><ForeName>Juan-Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>National Academy of Medicine of Colombia, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herr&#xe1;n</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltr&#xe1;n</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Medicine and Health Sciences, Doctoral Program in Biological and Biomedical Sciences, Universidad del Rosario, Bogota, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, Davis, CA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Clin Immunol</MedlineTA><NlmUniqueID>101271248</NlmUniqueID><ISSNLinking>1744-666X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Post-COVID syndrome</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">latent autoimmunity</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>6</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35658801</ArticleId><ArticleId IdType="doi">10.1080/1744666X.2022.2085561</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>